{
    "nctId": "NCT00235937",
    "briefTitle": "Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex",
    "officialTitle": "An Open, Phase II Trial Assessing the Objective Response Rate After Combination of Arimidex\u00ae 1mg Per os/Day and Zoladex\u00ae 3.6 mg Sub Cut/Monthly as 1st Treatment for Premenopausal Receptor Positive Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "Determine the feasibility and efficacy of the combination of these 2 drugs in these patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent, premenopausal women 18 years or older, histologically or cytologically confirmed locally advanced or metastatic breast cancer, suitable for endocrine treatment, no curative treatment available,, one or more measurable lesions, life expectancy more than 6 months, normal biological parameters.\n\nExclusion Criteria:\n\n* Presence of life-threatening metastases, previous endocrine therapy or chemotherapy for advanced or metastatic disease, any previous treatment with hormone (LH-RH) severe or uncontrolled systemic disease, pituitary adenoma, High risk of medullar compression.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}